Related Experiment Videos
Rocuronium and anaphylaxis--a statistical challenge
1Department of Anaesthesiology, National Hospital (Rikshospitalet), Oslo, Norway. j.h.laake@basalmed.uio.no
Abstract:
Drug induced anaphylaxis is frequently attributed to the use of muscle relaxants during anaesthesia. Recently The Norwegian Medicines Agency recommended that rocuronium bromide (Esmeron) be withdrawn from routine practice due to frequent reports of anaphylaxis. Over a period of two and a half years approximately 150,000 patients received rocuronium as part of their anaesthesia. In this period the Norwegian drug authorities received 29 reports of anaphylaxis or anaphylactoid reactions in patients treated with rocuronium. This is in stark contrast to the situation in other Nordic countries where a total of only seven cases of anaphylaxis in approximately 800,000 patients treated with rocuronium had been recorded by December 2000. This situation highlights the many potential problems of the surveillance of adverse drug reactions: reporting bias may lead to an over-estimate of the risk of one drug compared to another, and the possibility of under-reporting of adverse events (due to a weak reporting culture) further limit the validity of such comparisons. The surveillance of adverse drug reactions also represents a statistical challenge. While adverse event reports may help us to estimate the anaphylaxis rate we need to appreciate the uncertainty of such estimates. Adverse reactions are rare, random, and mostly independent events, resulting from the successive exposure of patients to a low risk intervention. The frequency distribution of adverse events will therefore conform to that of a Poisson process. The resulting Poisson distribution may inform us about the variability of adverse event data. An understanding of these methodological problems and statistical challenges will allow anaesthesiologists to make informed decisions concerning the use of muscle relaxants and other drugs associated with severe adverse reactions.
Insights
Drug-induced anaphylaxis from rocuronium bromide (Esmeron) is a concern. Norway reported more cases than other Nordic countries, highlighting surveillance challenges and statistical uncertainties in adverse drug reaction monitoring.
Area of Science:
- Anesthesiology
- Pharmacovigilance
- Biostatistics
Background:
- Drug-induced anaphylaxis is a significant concern in anesthesia, often linked to muscle relaxants.
- Rocuronium bromide (Esmeron) use has been associated with frequent anaphylaxis reports in Norway.
- Comparisons with other Nordic countries reveal significant discrepancies in reported anaphylaxis rates for rocuronium.
Purpose of the Study:
- To analyze the reported rates of anaphylaxis associated with rocuronium bromide in Norway.
- To highlight methodological issues in adverse drug reaction surveillance, including reporting bias and under-reporting.
- To discuss the statistical challenges in estimating the true incidence of rare adverse events.
Main Methods:
- Comparative analysis of anaphylaxis reports between Norway and other Nordic countries for rocuronium use.
- Examination of data from approximately 150,000 patients in Norway and 800,000 in other Nordic countries.
- Application of Poisson process principles to understand the statistical distribution of rare adverse events.
Main Results:
- Norway reported 29 anaphylaxis cases among 150,000 patients receiving rocuronium.
- Other Nordic countries reported only 7 cases among approximately 800,000 patients treated with rocuronium.
- Significant disparities suggest potential issues with reporting culture and bias in pharmacovigilance.
Conclusions:
- Adverse drug reaction surveillance data requires careful interpretation due to potential biases and under-reporting.
- The statistical nature of rare events, often following a Poisson distribution, necessitates understanding variability in estimates.
- Anesthesiologists must be aware of these methodological and statistical challenges for informed decision-making regarding muscle relaxants.